<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Jessica Myers Schecter on Medium]]></title>
        <description><![CDATA[Stories by Jessica Myers Schecter on Medium]]></description>
        <link>https://medium.com/@jessica_86347?source=rss-476d0b9e1b4b------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*1CNpiHl6TPIFsxvlrVHFIg.jpeg</url>
            <title>Stories by Jessica Myers Schecter on Medium</title>
            <link>https://medium.com/@jessica_86347?source=rss-476d0b9e1b4b------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 11:30:29 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@jessica_86347/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Women + Movember]]></title>
            <link>https://medium.com/@jessica_86347/women-movember-e739a63c2f20?source=rss-476d0b9e1b4b------2</link>
            <guid isPermaLink="false">https://medium.com/p/e739a63c2f20</guid>
            <category><![CDATA[movember]]></category>
            <category><![CDATA[men-health]]></category>
            <category><![CDATA[prostate-cancer]]></category>
            <category><![CDATA[mens-health]]></category>
            <category><![CDATA[moustache-november]]></category>
            <dc:creator><![CDATA[Jessica Myers Schecter]]></dc:creator>
            <pubDate>Wed, 29 Nov 2017 19:47:03 GMT</pubDate>
            <atom:updated>2017-11-29T19:47:03.359Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/279/1*VHSVJ7aG7MMGBoPCaslZAQ.png" /></figure><p>Heather Mott is one of the <a href="https://us.movember.com/">Movember Foundation’s</a> top fundraisers.</p><p><a href="https://www.prostatepedia.net/pages/subscribe">Prostatepedia</a> spoke with her about raising money for men’s health.</p><h4>How did you become involved with Movember?</h4><p>Ms. Mott: This is my sixth year participating as a Mo Sista and raising funds for the cause. I don’t remember exactly how I heard about it, but I think it was through social media. It sounded interesting and fun and it benefits men’s health, so I started doing it.</p><p>When I started, Movember was more focused on prostate and testicular cancers, but now they’ve branched out into mental health awareness and healthy lifestyle activities.</p><h4>How can a woman participate?</h4><p>Ms. Mott: It is easy to get involved — all you have to do is sign up on their website. I try to do a different photo every day of the month. Since I am genetically-challenged to grow my own mustache, I usually order fake moustaches and take some selfies. Sometimes friends help me.</p><p>I’ve tried doing themes with some common factor across the different photos. For example, my theme for this year’s Movember campaign is photos of individuals in a role that serves the community. Today, I posted a photo with a Navy backdrop, thanking all those who serve or have served in the Navy. I’ve posted backgrounds with other public servants like teachers, those in the justice system, or first responders.</p><h4>What kind of themes have you used in the past?</h4><p>Ms. Mott: One year I had the different individuals from the Village People who sing the YMCA song. I had a cop, a construction worker, and all that. There hasn’t been a real rhyme or reason to the themes, just whatever strikes me that year.</p><h4>How do you get people to join your team?</h4><p>Ms. Mott: When I started, I didn’t join a team. Then the next year my company, Johnson &amp; Johnson (I’m at the Los Angeles Neutrogena facility) started a team. I joined them and this is our fifth year. We have new people each year and some reoccurring partners. We do a lot of recruiting onsite and there is some friendly competition. We have all kinds of events over the course of the month.</p><h4>Has your involvement in Movember had an impact on your community?</h4><p>I started with Movember because I thought it was an interesting way to raise awareness and help fund research. Then, about three years ago, my father was diagnosed with prostate cancer. Thanks in part to Movember awareness, he caught it so early that he was able to do active monitoring for a year. There wasn’t enough cancer to treat.</p><p>Last year, he went through treatment. Because he caught it so early, he went through a program called CyberKnife. He has had hardly any side effects, no pain, nausea, nothing that people tend to associate with cancer treatment.</p><p>My involvement in Movember impacted me personally and made a big difference in my father’s life.</p><h4>Would he have waited to be screened if you hadn’t been involved with Movember?</h4><p>Ms. Mott: He’s been a pretty healthy and health-conscious individual throughout his life, so he is pretty diligent about getting his annual checkups. Once he got to a certain age and was a little bit more aware, it definitely helped him. It helped him network, understand treatment options, and talk to others about it. I know that that’s something Movember is big on, raising awareness. There are networks out there to help you when you find out you have cancer. He was nervous at first, so it definitely helped him get through all of it. It helped him be conscious that it’s important to get these checkups, especially at a certain age.</p><h4>Does he participate in Movember along with you?</h4><p>Ms. Mott: He is a very active supporter, but he doesn’t have his own Mo Space or anything like that.</p><h4>You should set him up.</h4><p>Ms. Mott: [laughs] I know. He’s always had facial hair.</p><h4>He was already growing the moustache?</h4><p>Ms. Mott: Yes. He was growing long before.</p><h4>Do you have any thoughts for men or women who want to fundraise for Movember?</h4><p>Ms. Mott: I would love to see even more Mo Sistas, because we all have men we love in our lives. I became aware of Movember through social media, so I’m always posting through my social media platforms.</p><p>But I’ve also done some bake sales at a community brewery and I worked with local businesses to get the word out.</p><h4>Is it worth trying to get your company or place of work to organize a team?</h4><p>Ms. Mott: Yes. I work at a large company, so a lot of individuals here care about health. That has made it easier for us to have a team each year.</p><p>Last year, our goal was to raise $10,000; we raised about $13,750. It does help partially that I work with a large company, but this is something anybody can get behind.</p><h4>We all know at least one man who’s at least had a scare, right?</h4><p>Ms. Mott: Yes.</p><h4>Does your team have events throughout the month, or is it mainly just about getting together and raising as much money as you can?</h4><p>Ms. Mott: We have events. I’m co-leading our team here onsite this year. We have a Shave Off kick-off each year where all of the guys signed up come, and since we make men’s care products, they do a shave off together.</p><p>We then host different fundraising activities. This year we have a lot of healthy activity initiatives at Johnson &amp; Johnson. We’re doing some yoga and a Ping-Pong competition. People can buy-in to donate to the team; there will be some prizes at the end of the tournament.</p><p>We do different activities each year to keep it fun, engaging, and to generate funds. Johnson &amp; Johnson has a culture of supporting these types activities and there are other ways for companies to help. Companies often match donations.</p><h4>Any last thoughts for men who might want to participate?</h4><p>Ms. Mott: It’s so easy to sign up and get involved. It’s such a fun activity. Movember is a very engaging group. Their United States headquarters is in Culver City, CA — right next to us.</p><p>It’s a great way for men to touch base in a less formal environment, and it definitely builds a network, so that should you get diagnosed, you have others who understand, can offer support, and who have maybe been through it themselves.</p><p><a href="https://www.prostatepedia.net/pages/subscribe">Not a member? Join us.</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e739a63c2f20" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Facebook + Movember]]></title>
            <link>https://medium.com/@jessica_86347/facebook-movember-801c2eef0dd0?source=rss-476d0b9e1b4b------2</link>
            <guid isPermaLink="false">https://medium.com/p/801c2eef0dd0</guid>
            <category><![CDATA[cancer]]></category>
            <dc:creator><![CDATA[Jessica Myers Schecter]]></dc:creator>
            <pubDate>Tue, 28 Nov 2017 21:49:39 GMT</pubDate>
            <atom:updated>2017-11-28T21:49:39.871Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*I1uKKjFJPYJDjoRoBAbyJA.jpeg" /></figure><p>Andrew Hahn is one of <a href="https://us.movember.com/">Movember’s</a> top fundraisers.</p><p><a href="https://www.prostatepedia.net/">Prostatepedia</a> spoke to him about how he uses Facebook in the annual moustache-growing campaign.</p><h4>How did you become involved with Movember?</h4><p>Andrew Hahn: I knew a few people nine years ago who were growing mustaches. They looked silly, but it started a conversation about something that, at the age of 32, I wasn’t used to talking about: prostate and testicular cancer. I wanted to learn more about the movement and why they were doing it. My father, unfortunately, passed away from cancer when I was 24.</p><h4>I’m so sorry. That’s so young.</h4><p>Mr. Hahn: Thank you. He had a mustache his entire life. Even though he passed away from brain cancer, here was an amazing opportunity for me to connect with my dad and raise some important funds and to help people not go through what I went through.</p><p>I’ve been very fortunate: I’ve built teams and have raised over $150,000 in the last seven or eight years.</p><h4>What is your fundraising strategy?</h4><p>Mr. Hahn: Any charity or fundraising is important and phenomenal. Three out of four of us have someone who has been affected by cancer. You have friends who walk a 5K for breast cancer. That’s amazing. But you really get some empathy for growing a mustache for 30 days. It’s not just a Sunday morning.</p><p>I’ve never asked anyone for donations. I’m very proud of that. I’ve backhandedly guilted them into it.</p><p>Traditionally, I send out an email in late October. Sometimes I make a video, tell people what I’m doing, and talk about the mission to benefit all men.</p><p>I do a ton of social media posting. Anytime someone donates, I thank them, hyperlink them on Facebook, and say, “Thank you, Erin. Your contribution is amazing. If anyone wants to be as cool as Erin…” I do cool pictures.</p><p>Even though I haven’t asked them directly, everyone on social media just sees it going on. They see how long a month actually is. I take pictures of my mustache, and my family, and the people who donate. I wouldn’t say it’s easy. It’s actually a lot of work. It usually takes about 80–100 hours per Movember campaign.</p><h4>Just in terms of the social media posting and curating?</h4><p>Mr. Hahn: The social media is one part. I put a huge team together within a company and we advertise and market together. We got approval from the company to design T-shirts so anytime someone donated $50 or more, they got a T-shirt. Then all of a sudden, people were wearing T-shirts around the office and others were asking, “What did you get that t-shirt for?” It’s a lot of work.</p><h4>You must work closely with your company then?</h4><p>Mr. Hahn: Yes, with my former company. It was great press for them because one year we raised over $50,000. Being a large tech company, it was just a great thing for them to brag about.</p><h4>Most large companies have some kind of philanthropy branch, don’t they?</h4><p>Mr. Hahn: Exactly. My buddy just donated yesterday. He works with Google and they matched his contribution dollar for dollar, which is pretty awesome.</p><h4>Do you have any thoughts for men who want to participate?</h4><p>Mr. Hahn: I’m going on 41 this year. I see huge stigmas about men going to the doctor, being proactive, and — let’s be candid — guys don’t want a finger up their ass. There’s this saying: if you think a finger up your butt once a year is painful, God forbid you have to get that done every day while dealing with prostate cancer.</p><p>Early detection, prevention, and awareness are the only fights we have. The money that we’re raising and the cause we’re helping isn’t for a cure; it’s for early prevention, awareness, discussion, and those type of things.</p><h4>Screening.</h4><p>Mr. Hahn: Exactly.</p><h4>What about the mental health piece? Because that has come into play in the last few years for Movember.</h4><p>Mr. Hahn: As you know, three out of four suicides are men. My wife’s dad, unfortunately, committed suicide. She’s Asian, and in her culture, they’re even quieter about talking about mental health.</p><p>I had a buddy who I wouldn’t say was suicidal, but he was really down from being out of work and being a dad. My awareness was not only to have conversations with him, but to also ask how he was doing and to take it deeper. “How are you feeling? What’s your plan?” Saying “You can come to me for anything,”<strong> </strong>is something I probably wouldn’t have been as comfortable doing without Movember. It challenges your manhood. You don’t have a job. Your wife’s on you. It’s a great campaign to have in parallel for that reason.</p><h4>What you’re saying is the awareness campaigns encourage men to reach out to those who are suffering, and not just for men who are suffering to reach out to others?</h4><p>Mr. Hahn: Yeah. This is one of my best friends, but guys are bros. We golf, we drink, we talk about fantasy sports. We don’t really talk about our feelings. Traditionally, I would’ve said, “Hey man, how are you doing?” He’d say, “Oh, I’m okay. It’s okay.” I’d think, “You’ll be fine. You’re strong.” Then we’d talk about beer again.</p><p>The elevated comfort zone and awareness enabled and empowered me to be more aware, to have a larger conversation about his overall health, his well-being, and his plan. He knew that if it was two in the morning, he could call me and I’d be there for him. It’s just a verbal hug.</p><h4>The Movember movement seems to be a cultural phenomenon, at least from the outside.</h4><p>Mr. Hahn: It is. There are so many guys who grow mustaches, some for Movember, and some because it’s a hipster thing to do in November.</p><p>Are we upset when someone grows a mustache and doesn’t raise money? As long as it starts a conversation, it’s okay.</p><p>I’m in sales and I’m client-facing all the time. I used to be afraid that if I had a mustache, people would look at me funny. Now, I walk into a room and I point out, “Hey, I know I look silly. I’m doing this for Movember to raise money for awareness.” It changes the entire dynamic of the conversation. I go from being a salesperson to a human starting a conversation.</p><p>It really is a phenomenon. Two-thirds of the people who donate to me are not good friends. They’re people that I went to high school with, or people that I worked with 10 years ago. The common theme is they’ve been affected by cancer. The average donation I get is probably about $80. I am blown away by that.</p><h4>I would have thought $20 or $30.</h4><p>Hahn: No. I got $180 donation yesterday from someone I haven’t seen or spoke to in years. I get a $1,000 donation each year from someone who I see less than once a year. These are people who have been affected and want to do something. They know Movember is a great organization.</p><h4>You said you spend a lot of time on social media. Are there certain channels that you favor over others, say Facebook versus Instagram?</h4><p>Mr. Hahn: I do Facebook to thank people more than Instagram. I was a little late to Instagram. On Facebook I have 1,000 friends while on Instagram I have about 200. I just have a greater reach and impact on Facebook.</p><p>I use the Movember filter where it says, “Thank you for your donation.” The great thing about those posts is not only am I thanking them and creating awareness, it also makes them feel good, and all their friends know that they give. It’s a win-win-win.</p><h4>Positive reinforcement?</h4><p>Mr. Hahn: Well, it is. And it candidly<strong> </strong>pokes at your other friends who haven’t donated. Of my 20 best friends, I think only three of them donate to Movember. The people who tend to donate are those who have been impacted and affected.</p><h4>Most of us have at least one man in our family who has experienced depression if not prostate cancer itself. If you combine both of those things together, that’s quite a lot of men impacted.</h4><p>Mr. Hahn: Exactly. Movember is still known for prostate and testicular cancer awareness. The suicide prevention is a new initiative that most people don’t associate with Movemeber.</p><h4>I wonder if people view Movember as a prostate cancer nonprofit or just a men’s health group.</h4><p>Mr. Hahn: I think they view Movember as men’s health and something related to cancer at this point, but like I said, men don’t go to the doctor and men don’t talk about their feelings.</p><h4>That may be changing as men come of age in the social media era.</h4><p>Mr. Hahn: It will change. If 20% of guys are comfortable talking now, maybe it’ll rise to 30% or 40%. I see my friends so infrequently because I have a family and a job, so when I see them, I really just want to talk about sports, beer, and golf, even if something’s really weighing on me.</p><p>In my experience, when I tell someone what’s going wrong, they’re apathetic. They’ll ask a question, but I don’t think the dialogue continues with men. They ask if you’re okay, and then they take it one level deeper, but your friends aren’t trying to be your therapist. Part of the mental awareness is making men feel okay to talk to someone professional.</p><h4>Any last thoughts for men who want to participate or who are already participating but want to increase their reach?</h4><p>Mr. Hahn: When people are on the fence, unsure of whether or not they want to participate, I have one great tool to encourage people to participate. I tell them: Just start growing out your beard for a week. Bring it down to a mustache, and I promise you, a week into it, you’re going to be so into it and love it. I would say 10 out of 10 people that start on the fence end up actually growing out the Mo.</p><p>Money is great, but conversations can be great, too. If they have one conversation a day about why they have a mustache, they’re raising awareness and education and a level of comfort. Like I said, almost equally important to raising money is raising awareness and starting those conversations.</p><h4>What about getting women to participate?</h4><p>Mr, Hahn: I’m so glad you brought that up because at my former company, over 40% of the donations were brought in by Mo Sistas. Obviously, they can’t grow a mustache, but it impacts their husbands, brothers, boyfriends, sons and dads, so it’s equally important to them. They can take pictures with funny, fake mustaches. Sometimes we would combine a Mo Bro and a Mo Sis and they would rally together.</p><p>The joke make to my single friends is that 9 out of 10 girls do not like mustaches, but that one girl <em>really</em> likes mustaches. When I was single and had a mustache, I had a little fun.</p><p><a href="https://www.prostatepedia.net/">Join Prostatepedia to read more about prostate cancer and its treatment.</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=801c2eef0dd0" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Moustache: A Fun Approach To A Serious Problem]]></title>
            <link>https://medium.com/@jessica_86347/the-moustache-a-fun-approach-to-a-serious-problem-65e15799a05a?source=rss-476d0b9e1b4b------2</link>
            <guid isPermaLink="false">https://medium.com/p/65e15799a05a</guid>
            <category><![CDATA[mens-health]]></category>
            <category><![CDATA[cancer]]></category>
            <category><![CDATA[prostatepedia]]></category>
            <category><![CDATA[movember]]></category>
            <category><![CDATA[prostate-cancer]]></category>
            <dc:creator><![CDATA[Jessica Myers Schecter]]></dc:creator>
            <pubDate>Thu, 09 Nov 2017 22:00:28 GMT</pubDate>
            <atom:updated>2017-11-09T22:00:28.155Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/421/1*Uv-LfJXfTve9WTx-Ef8OJw.jpeg" /></figure><p>Sandy Goodman is one of <a href="https://us.movember.com/">Movember’s</a> top fundraisers. <a href="https://www.prostatepedia.net/pages/subscribe">Prostatepedia</a> spoke to him about their annual moustache-growing campaign.</p><h4>What is Movember?</h4><p>Sandy Goodman: Movember is a fun approach to a serious problem. A bunch of guys sat down over some beers and dreamed up this way to follow the lead of breast cancer awareness advocates, who had been doing such a great job talking to women about early detection. These guys talked about what could be done for men. It’s grown into something much larger. The bottom line: guys don’t talk and men are dying too young (6 years earlier than women, on average).</p><p>Men are dying too young, and, for Movember, the simple solution is the moustache. The moustache is just our ribbon — it’s our banner. I don’t grow a moustache normally. Because I do it once a year, everyone asks why I’m growing one. It sparks the conversation.</p><p>Movember has been very innovative. They’ve made all the fundraising and gift-giving tools available online to everybody. An incredible amount of partnership and research has been funded through Movember. The back end — what the money is going towards — has real outcomes.</p><p>I’m happy to be a part of something that’s fun, and I’m proud to be part of something that’s truly making a difference.</p><h4>Sounds like the annual campaign isn’t just about fundraising, but is also a way to start talking about some of these issues.</h4><p>Sandy Goodman: Yeah, that’s right. It’s definitely all about sparking conversation. Men are terrible at making doctor appointments. Men are terrible at following up on doctor appointments. Men are terrible about checking themselves and being aware of what’s going on. To the extent that we can just spark conversation is a big impact.</p><p>Movember used to say that one moustache reaches an average of 100 people in a month. The number of emails you send out and share, Facebook posts, blog posts, the pictures — the reach is large and it just multiplies.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/192/1*0FbRflo7TxWUcGVgc4Ndbg.jpeg" /></figure><p>I’d be surprised to find anyone on the globe now who doesn’t understand what a moustache during the month of November means.</p><p>For me, it’s just about being involved with something. We all need to give back. I’m a huge believer in lifting with your pinkies as a group. It’s such a powerful thing when we all just lift together.</p><h4>How did you get involved with Movember?</h4><p>Sandy Goodman: I got involved 10 years ago because my father-in-law was diagnosed with prostate cancer. He had been doing all the right things. He went to his doctor for PSA and DRE exams every year. When his doctor saw something he didn’t like, he said, “You have an elevated PSA score and need to come back.”</p><p>At the time, he was getting remarried. His brother had had some complications after a prostatectomy, so my father-in-law was afraid to go back. He didn’t go back until a year later when he was doubled over in pain and they said it was too late. He was terminally ill with prostate cancer. It had spread. They gave him three years to live; he made it eight years, but it was not a very good eight years.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*8fDkinvN9xcBy47HuZfK8Q.jpeg" /></figure><p>Early detection is so important, but beyond early detection is early action. My father-in-law did the right things, but then didn’t follow through… he didn’t take action. It was sad to watch this whole process. It was especially terrible, because it was completely avoidable.</p><p>At the time, I knew nothing about my prostate. I didn’t know what it did. I didn’t really know where it was and I never checked it. I was 45 years old. None of my friends knew anything about their prostates, either. We never checked our testicles or any of that stuff.</p><p>At the same time, a work friend’s dad had cancer. He was getting involved with Movember. He started a team and I joined him. Movember had only been in the United States for a year at the time.</p><p>It was a fun approach to a serious problem, which was right up my alley. I grew a moustache, got hooked, and I’ve been growing for 10 years now. I’ve been talking to everyone I can, all my bros.</p><h4>Movember has had the viral social media aspect going for it.</h4><p>Sandy Goodman: Completely. I started a golf tournament for our team 5 years ago. It’s grown. My goal was to bring the Movember message to my local community. I was walking around the South Bay and people would recognize that I had grown a moustache, but I think they saw me as a novelty. I wanted to do more. The golf tournament brings in local businesses. They set up on every other hole, so it’s an interactive experience. It’s a fun day. One of them sponsors the team photos of everyone holding up the tournament banner.</p><p>This year, instead of having a professional photographer there to take the picture, we’re asking the players to take the pictures with their own cameras and phones, so they’ll have it immediately. Then they can share and post their photos with hash tags. It’s just another way to keep the message growing virally.</p><p>There are new ideas every year.</p><h4>What has been your own approach to Movember?</h4><p>Sandy Goodman: It’s changed over the years. At first, it was about getting people on the team. We’ve had as many as 80 people on a team and we’ve had as few as 20. I haven’t even really started building a team yet for this year. I used to start up on September 15, the day the website goes up, but it was a bit early. I just sent my first email for recruiting.</p><p>Originally, we just had a get-together with the guys. Then, we connected with some local bars and existing local events. Now we help promote. Bars and restaurants are happy for us to bring our crew, so we’ve had a lot of success with that. If there’s too much happening on the calendar, though, people can get burnt out, so we take that into consideration.</p><p>Movember has made it easier to host an event. Once you’re signed up, you can send invites to your friends or you can post events publicly. It’s fantastic. You could post a keg party if you wanted and ask for donations as admission.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Z3MD6iKg1msi1cXp4IaZCw.jpeg" /></figure><p>When they were in college, I helped my sons set up their own team, The Buffalo Mo Bros. I encouraged them to use those tools to set up keg parties and things like that. It was super easy. It’s about getting together, having fun, and raising awareness and some money.</p><h4>How do you motivate people to donate to a cause like this?</h4><p>Sandy Goodman: In the beginning, I fundraised almost exclusively through email. I would send out about eight emails throughout the campaign. I started with the kickoff, maybe something for Halloween, then Veterans Day, and halfway there’s the golf tournament and then the wrap-up.</p><p>I would always attach a personal message. I would cut my group into subgroups, such as work friends or high school friends, and then cater the messages to them. Movember allows you to upload pictures to the site, so I do that, and they can see my progress.</p><p>Now, I focus exclusively on the golf tournament, because it’s just a big event. It raises about $50,000. I organize everything.</p><p>For whatever reason, I am fortunate to have some very generous friends. Everyone understood that I was passionate about it and that resonated. I was passionate because of my father-in-law. I was passionate because I have three sons who have a history to be concerned with because they’re two and a half times more likely to get it than I am.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*1Lo2Bb011393YEPg03D4Hg.jpeg" /></figure><p>What works for my fundraising is email campaigns and being thoughtful about how I word the emails and who I send them to.</p><p>I’ve been doing this for 10 years. I’ve been the top United States fundraiser for the past 8 years. The individual who has raised the MOst MOney is called the MoMo. It’s a title I love. I would love to retain it.</p><p>I imagine if you’ve been doing this for eight years, you must have a core group of people who campaign with you every year?</p><p>Sandy Goodman: I do, but people come in and out. It’s hard to maintain the passion. There are many charities that compete for our attention and our dollars. People have other things in their lives. Sometimes life throws you a curve ball, and your focus and priorities just change.</p><p>For example, one of the guys who has been with me all these years just told me: “My mother-in-law has breast cancer. So I’ve decided to focus on the breast cancer walk this year.” I think that’s great. There’s nothing wrong with that. I miss him, but he’s still doing great things.</p><p>For me, it’s just about being involved with something. It’s such a powerful thing when we all lift together. It’s about numbers.</p><blockquote>It’s about having a clear message and a clear path for success.</blockquote><p>You have to make it frictionless for people so that they can just click and be done. If people don’t see a hyperlink and they don’t understand your methods, you’re not going to win. Movember has been fantastic at that. They get that need for ease. That’s why they were trailblazers and why they were able to have such success and to grow so quickly.</p><p>They made it frictionless. They made itasy for people to understand the message, to follow somebody who’s passionate and having fun and to see your progress. Pictures and emails are template-driven, so they allow you to spin to your group, update, and customize your message. “Just click here.” It’s that simple.</p><h4>What are your tips for men who want to start their own group?</h4><p>Sandy Goodman: Have fun. Be passionate. And do the work. There’s a full spectrum of Mo Bros and Mo Sisters. There are people out there who sign up and they’ve raised zero dollars, but they have fun and they have an excuse to spark conversations. That’s great. They’re doing something and making a difference. If one moustache saves one life, even if you haven’t raised any dollars, that’s fantastic.</p><p>On the other end of the spectrum, some people just get really into it. They get passionate, organized, do the hard work, and they raise a lot of money and awareness. It’s a balance between both.</p><h4>Do you have any advice for patients or their loved ones who want to participate?</h4><p>Sandy Goodman: I watched my father-in-law suffer. It was a very difficult experience for everybody — obviously for him — but also for all his family members. Once he had prostate cancer, we learned that it was so confusing to find and understand the resources available, the best course of action, or the best treatments.</p><p>Movember had resources that were really comforting and helpful and focused on care (LIVESTRONG at the time). Knowing that they’re doing the research and the work is comforting also.</p><p>Under “About Us,” they have information on the work that they’re doing. There are over 1,200 projects funded by Movember in all areas of men’s health: prostate cancer, testicular cancer, and mental health and suicide prevention.</p><p>They also provide links to other resources. They have hotlines for people to call for more information and support.</p><p>Resources for mental health have really grown in prominence at Movember over the past few years, mostly in response to the mental anguish that you go through when faced with any cancer and not knowing who to talk to. When you consider that three out of four suicides are men, it’s a huge issue at all ages.</p><p>I never want to get a message from someone saying they’re glad I’m doing this because they’ve just been diagnosed with prostate cancer. That’s terrible. But the fact that they were diagnosed and they’re taking action is fantastic, because they’re reaching out. They’ve seen me, my passion, and they’ve seen my moustache every year.</p><p>I always pick up the phone. I try to help however I can. If I can provide a resource through Movember, I always do that, but it’s a tough journey.</p><h4>Most people with prostate cancer will die of something else.</h4><p>Sandy Goodman: That’s true. For those who already have prostate cancer, it’s the treatment and it’s the side effects that are difficult.</p><p>I have several friends that have gone through complete prostatectomies and several going through active surveillance. It’s not an easy journey, even if it’s super successful. It just takes time.</p><h4>Do you still feel men don’t want to talk about prostate cancer?</h4><p>Sandy Goodman: That’s changing a little. I have two good friends who have had prostatectomies and they’ve had some very serious side effects. They are extremely open about wearing diapers and the other issues. That conversation wouldn’t have happened 10 years ago. I would have waived them off like: “I don’t want to hear that.” Now, I’m open to it, everyone around me is open to it, and it’s not taboo anymore. It’s more about being there for them than anything else.</p><blockquote>The message is being heard.</blockquote><h4>Do you think that this change is due to efforts like Movember’s annual campaign, or do you think society is evolving?</h4><p>Sandy Goodman: I think it’s a combination. It’s not one or the other. People are coming of age in a more communicative era. We have Facebook and social media and charities out there are promoting and discussing these issues.</p><h4>We’re more accustomed to sharing our emotions as a culture?</h4><p>Sandy Goodman: Yes. We share a lot. We share everything on the worldwide web. There it’s frictionless, and the messages are bouncing around at hyper speed all the time. Sometimes more than you want. But that’s for the best when you’re talking about things that in the past were not discussed and should be.</p><h4>Depression and suicide?</h4><p>Sandy Goodman: One hundred percent. People suffer on their own for many reasons, including cancer. That’s the main message of Movember: talk, listen, and be there. I’ve picked up the phone to check on people many times over the last couple years, and we just have a conversation. Other times people have reached out to me when I wasn’t feeling great about things. I would just be honest and say: “I just need to talk to someone right now.”</p><p>For me, that support is completely thanks to Movember and their message. I try to practice what they preach, but it’s not always easy. We’re guys. We still grew up being guys. We don’t cry. We say, put a Band-Aid on it, you’ll be fine. But that’s not as powerful as reaching out.</p><p><a href="https://www.prostatepedia.net/">Join Prostatepedia to learn more about prostate cancer and its treatment.</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=65e15799a05a" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[PET/CT Imaging + Radiation Therapy]]></title>
            <link>https://medium.com/@jessica_86347/pet-ct-imaging-radiation-therapy-9d11f542143d?source=rss-476d0b9e1b4b------2</link>
            <guid isPermaLink="false">https://medium.com/p/9d11f542143d</guid>
            <category><![CDATA[cancer-imaging]]></category>
            <category><![CDATA[prostate-cancer]]></category>
            <category><![CDATA[prostate-radiation]]></category>
            <category><![CDATA[pet-ct-imaging-prostate]]></category>
            <category><![CDATA[cancer]]></category>
            <dc:creator><![CDATA[Jessica Myers Schecter]]></dc:creator>
            <pubDate>Wed, 11 Oct 2017 18:34:27 GMT</pubDate>
            <atom:updated>2017-10-11T18:34:27.891Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*98PG52H3ZurWOUOQdDO11Q.jpeg" /></figure><p>Dr. Michael Zelefsky, a radiation oncologist, is Professor of Radiation Oncology, Chief of the Brachytherapy Service, and Co-Leader of the Genitourinary Disease Management Team at Memorial Sloan Kettering Cancer Center in New York City.</p><p><a href="https://www.prostatepedia.net/">Prostatepedia </a>recently spoke with him about how advances in imaging have impacted radiation therapy.</p><h4>What role does imaging now play in radiation therapy?</h4><p>Dr. Zelefsky: Radiation therapy has been linked to imaging for many years. In the late 1970s and early 1980s with the advent of the CAT scan, those images were used in the treatment planning process to provide greater accuracy for targeting the radiation. Over the ensuing 20–30 years, there have been significant advances in imaging, from CAT scanning to MRI, and from multiparametric MRI to molecular imaging. These advances in diagnostic imaging continue to be linked to radiation treatment. We use multiparametric MRI imaging to target radiation to the prostate with exquisite precision. Just as importantly, we use these technologies to understand the geometry and anatomy of the surrounding normal tissues. For the prostate, that could mean the bladder, rectum, bowels, and even specific anatomic regions like the bladder neck and the neurovascular bundles that control erectile function.</p><p>Advances in imaging have allowed us to visualize these normal tissue structures, and this information is incorporated into treatment planning, giving us a way to deliver the radiation with a precision we’ve never had before.</p><h4>What sorts of changes do you think are on the horizon as we develop better imaging techniques?</h4><p>Dr. Zelefsky: We have successfully moved from CT-based imaging to MR-based imaging. Now, we commonly use MRI and fuse those images with the CAT scan. At Memorial Sloan Kettering, we have moved to the next step, which is pure MRI-based planning. This means we don’t need the intermediary step of a CT scan anymore. We can plan directly off the MRI, and we map everything out from these sets of specific We’ve also moved beyond MRI to what we call multiparametric MRI. We look at different sequences and formats of the MRI, including dynamic contrast enhanced imaging, and diffusion-weighted imaging to give us further information about the location of the disease within the prostate, which is called the dominant intraprostatic lesion (DIL). This dominant intraprostatic lesion is an important area to target because recurrences after radiation stem from regrowth of disease from that initial site of disease in the prostate.</p><p>Radiation oncologists are recognizing that there may be opportunities to intensify the focus of the radiation to the DIL to improve the tumor control rates with radiation. We have moved from CT-based to MR-based radiation therapy to pure MRI-based planning, and now we incorporate important information from multiparametric imaging. In the future, we’ll also incorporate molecular imaging, which comes from advanced nuclear medicine studies.</p><p><a href="https://www.prostatepedia.net/pages/subscribe">Join Prostatepedia to read the rest of the conversation.</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=9d11f542143d" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Patients Speak: Facing Mortality]]></title>
            <link>https://medium.com/@jessica_86347/patients-speak-facing-mortality-fd34014a32a7?source=rss-476d0b9e1b4b------2</link>
            <guid isPermaLink="false">https://medium.com/p/fd34014a32a7</guid>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Jessica Myers Schecter]]></dc:creator>
            <pubDate>Mon, 09 Oct 2017 20:32:57 GMT</pubDate>
            <atom:updated>2017-10-09T20:32:57.576Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Vk3F6gCy0TItxG8pi-5PQA.jpeg" /></figure><p>Mr. Spencer Le Gate spoke to <a href="https://www.prostatepedia.net/">Prostatepedia </a>about his prostate cancer journey and his role in his local support group.</p><p><strong><em>How did you find out that you had prostate cancer?</em></strong></p><p>Mr. Spencer Le Gate: My family doctor put me on a small dose of a statin drug for cholesterol back in 2000. He had the good sense to give me a blood test every three or four months to check all my vital organs for any problems. At the end of 2007, he noticed that my PSA had started to rise. He asked if I knew anything about prostate cancer. Just a month prior, a childhood best friend had died from prostate cancer, so that was my introduction.</p><p>We watched my PSA for about a year, and then, in early 2009, I had a biopsy. We determined that mine was not the most aggressive form, so given all of the options, brachytherapy seemed like a good choice. I had the procedure in May of 2009. After that, there was a small spike in my PSA, which we all hoped would diminish as often happens after treatment. Almost two years later, my PSA had gone from around 1 up to almost 11, and that meant I had a recurrence of prostate cancer. Around early 2013, I had a biopsy that confirmed that I was recurrent nonmetastatic. I went on Lupron (leuprolide), which brought my PSA count down very nicely, so I asked if I could do it intermittently.</p><p><strong><em>You asked for that rather than the doctor suggesting it to you?</em></strong></p><p>Mr. Le Gate: Yes. I wanted the vacation because, of course, I experienced side effects.</p><p><strong><em>What kinds of side effects did you experience on Lupron (leuprolide)? How did you manage them?</em></strong></p><p>Mr. Le Gate: The side effects for me were, of course, the most common: hot flashes. At one point, I did have a Depo-Provera (medroxyprogesterone) shot, which diminished the hot flashes pretty well. The others were loss of libido and muscle weakness. I have lost muscle mass throughout my body, but particularly, in my legs. My muscles atrophied.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ZTGELH6VmiTQoZCtLT4XDQ.jpeg" /></figure><p><strong><em>Were any of these side effects severe?</em></strong></p><p>Mr. Le Gate: I would say, for the first round of my treatment, not so much. But since I went back on Lupron (leuprolide) in 2013, they are more pronounced. When I took the vacation, my PSA went up alarmingly. In other words, it was worse than that scary doubling threshold in three months.</p><p><strong><em>Did they put you back on the Lupron (leuprolide) as soon as that started to happen?</em></strong></p><p>Mr. Le Gate: I’ve been on the Lupron (leuprolide) for almost two years. Now, when I get up in the morning, my legs are painful and I’m a little rickety. Despite the fact that I’ll be 75 in a few months, my legs have been good to me, and I’ve led a very active lifestyle. The pain I feel now in the legs is not just the inevitably of age, but the Lupron (leuprolide).</p><p><strong><em>Does exercise help with the side effects?</em></strong></p><p>Mr. Le Gate: Exercise does. I have backslid some, but until about a year ago, I had a trainer. I went several times a week. I took a 12-week course of training sponsored by a local cancer organization during the intermittent period and it was very beneficial. Should I get the motivation to get back to exercise, it would help me a lot. I am still active and hands-on in my profession. I’m a general contractor. It’s a pretty active job, and I’m up and down all the time. But I learned very quickly once I started aerobic exercise, that it’s more effective than getting up every morning and putting on my tool belt.</p><p><strong><em>Is there anything else that you do to manage the side effects?</em></strong></p><p>Mr. Le Gate: Of course, the change in your mental state. When I’m not working, I’m a person who spends a lot of time reading, and before I decided to become a contractor, I had a pretty good education. I have some sense of my cognition, and I think that your overall mental state has an effect on how well you feel.</p><p><strong><em>Did that go away when you went on the intermittent period?</em></strong></p><p>Mr. Le Gate: It did. Most everything went away. I only had a year. During the intermittent period, I took that phenomenal 12-week course.</p><blockquote>We met twice a week for two hours of rigorous training, weightlifting — everything. It was really eye opening for me.</blockquote><p><strong><em>Are you saying the exercise and training impacted the cognitive side effects you were feeling as well?</em></strong></p><p>Mr. Le Gate: Oh, yeah. I think it did. I had some sense of that even before I had cancer. If you’re physically active, there is a positive mental effect to that. Again, some of these things are just so blurred. How much of it is due to aging, and how much is just the burden of a disease that — at this point — cannot be cured?</p><p><strong><em>Stress, you mean?</em></strong></p><p>Mr. Le Gate: Yes, stress. Also, I always have been a bit anxious. Now I think I have to be more careful about managing my anxieties. I mean, I think there’s so much of this disease that can be managed. You can manage it. I don’t have a metastasis. So I’m not in a worse position. I attend a monthly prostate cancer support group here in Sacramento, California. It’s one of the best things I’ve done. I’ve gotten involved in it, and I’ve actually had the good fortune to be asked to lead groups, come up with ideas, and answer folk’s questions.</p><blockquote>I’ve had a very healthy life and getting a major disease like this has been instructive.</blockquote><p>I started reading and writing more because of it, even just letters to the paper, letters to friends.</p><p><strong><em>About your disease?</em></strong></p><p>Mr. Le Gate: Not necessarily, no. I’m a political person on the progressive side. I have very strong opinions that I don’t mind sharing. Of course, I’m obliged to do more reading and be more thoughtful about my politics. I think having prostate cancer at this stage of my life has pushed me into this, and I take a great deal of satisfaction out of doing it now.</p><p><strong><em>What advice would you have for a man diagnosed with this disease?</em></strong></p><p>Mr. Le Gate: Find out all you can. Get involved in a group. Neither my oncologist nor urologist ever mentioned support groups. I discovered this just by chance when I was well into the recurrent part of my disease. Had I known that there was such a group when I was first diagnosed, I would’ve been better prepared to make decisions. Your doctor is a human being who can make good and bad choices. You need to be proactive.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*uOGimr6TG6pz8Xme8m9J4g.jpeg" /></figure><p>I was fairly proactive, but when I first was diagnosed with the disease, had I known there was a support group, I would’ve learned about a number of other options. For example, there’s a group in San Francisco called The Second Opinion. Once you get a diagnosis — for no charge at all — you can meet with a group of doctors and discuss your options. I never knew there was such a thing before. Everybody who’s ever discussed the options thoroughly and looked at all sides of the coin can set their mind at ease before they make any decisions.</p><p><strong><em>Are there other ways that the prostate cancer diagnosis might have had a positive impact on you?</em></strong></p><p>Mr. Le Gate: After a lifetime without serious health problems, it’s not a bad thing to realize that you’re mortal. I think it’s made me more responsible about whatever time is left of me. I want to use my time the best way I can and to learn something, even if it’s just to learn something about the disease. There’s so much to learn about healthcare and the science of treating with medicine, but most people, if they’re healthy, simply ignore this. To be more informed in this way, and to have the disease yourself — if you’re smart and if you have a sense of humanity — you’re going to think about other people who have the disease and be more sympathetic to others.</p><p><strong><em>The diagnosis has made you more —</em></strong></p><p>Mr. Le Gate: Empathetic. I want to reach out to the people I see at my support groups because I know something about the disease, especially for those who have just recently been diagnosed. Because I know a bit more, because I’m old hat, if I’m able to do the slightest thing to relieve their anxieties and fears, that’s a good thing. I’m hopeful that I can put together some sessions at my prostate cancer support group where participants can discuss their mental state. At the last meeting, when I was asked to be the facilitator, I came up with the idea to put together a questionnaire, which would be voluntary and anonymous. I want to see what people have done to mitigate, find some distractions, and to discuss anxieties.</p><p>I’ve noticed in our group that we’ve discussed the mechanics more than the emotional. You have to be careful that you don’t make this into a weepy, touchy-feely thing. I’m trying to navigate it so that we can discuss our emotional things in a sensible way that’s helpful, that doesn’t make people more fearful.</p><p><strong><em>You want it to be a positive experience?</em></strong></p><p>Mr. Le Gate: Exactly. I was pleasantly surprised when I raised the point, which was so different than the things we usually talk about. We usually talk about where someone is in their treatment. The response was relatively positive from people.</p><p>It’s an Us TOO through the University of California Davis Medical Center and Dignity Health. We alternate between those two venues. I’ve been with this group about three years.</p><blockquote>I’m not a person who joins things, but it’s become an important part of my life.</blockquote><p>I have the support of my peer navigator, Bill Doss, and our Director, Beverly Nicholson. They are just fabulous people. I’ve really gotten a lot out of it, and I think others have too. It helps to be almost 75 years old and still have your wits about you. To realize your experiences in life could be useful for a lot of other people. That’s what’s working for me.</p><p><a href="https://www.prostatepedia.net/pages/subscribe">Not a member of Prostatepedia? Join us.</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=fd34014a32a7" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Prostate Cancer Genomics In The Clinic]]></title>
            <link>https://medium.com/@jessica_86347/prostate-cancer-genomics-in-the-clinic-2fcb609fa8a0?source=rss-476d0b9e1b4b------2</link>
            <guid isPermaLink="false">https://medium.com/p/2fcb609fa8a0</guid>
            <category><![CDATA[cancer]]></category>
            <category><![CDATA[prostate]]></category>
            <category><![CDATA[genomics]]></category>
            <category><![CDATA[mens-health]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Jessica Myers Schecter]]></dc:creator>
            <pubDate>Wed, 15 Mar 2017 23:36:54 GMT</pubDate>
            <atom:updated>2017-03-15T23:36:54.127Z</atom:updated>
            <content:encoded><![CDATA[<p>Dr. Alicia Morgans is a medical oncologist at Vanderbilt-Ingram Cancer Center in Nashville, TN.</p><p>She specializes in treating advanced prostate cancer. She is particularly interested in addressing treatment side effects and in how men with advanced prostate cancer make treatment decisions.</p><p><a href="http://www.prostatepedia.net/">Prostatepedia</a> spoke with her recently about how genomics is — and isn’t — being used in the clinic.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/611/0*luJ1egYSqkPYcqcV." /></figure><h3>What is genomics versus genetics?</h3><p>Dr. Morgans: Genetics looks at different genes that can be passed on and inherited through different generations to give you certain traits or different features, like eye or hair color. Genomics for oncology is the study of the genes that alter a cancer’s behavior or growth. It involves our understanding of what is driving a cancer’s growth in a particular person.</p><h3>Are we currently using genomics for screening prostate cancer?</h3><p>Dr. Morgans: We use genetics in that we think about men with a first-degree relative with prostate cancer as being at higher risk. Some organizations suggest that men with a first-degree relative should start screening for prostate cancer at an earlier age, though with the United States Preventive Services Task Force (USPSTF) recommendations, things are a little bit murky right now.</p><p>We think about people with a family history of breast and ovarian cancer who have BRCA1 and BRAC2 mutations as being an additional group who may think earlier about screening for prostate cancer.</p><p>But we’re not necessarily using genomics in the screening setting yet. We use genomics after we have screened someone and taken a biopsy. Genomics can help us predict who may have an aggressive cancer and who may have a less aggressive cancer that can be followed with surveillance instead of treated immediately with surgery or radiation.</p><h3>How are we using genomics to select initial treatments?</h3><p>Dr. Morgans: There are some tests that men can use at the time of prostate cancer biopsy or after a prostatectomy that help them and their doctors think about how likely their cancer is to come back, to become metastatic, or to cause them to dieof prostate cancer. Those are tests urologists most commonly use.</p><p>Some are used when men get a biopsy and some, like the Decipher test, are used on a prostatectomy specimen. <a href="https://genomedx.com/">GenomeDX</a>, the company that makes Decipher, just announced a biopsy product to predict the risk of metastatic disease, as well.</p><p>There is the <a href="https://prolaris.com/">Prolaris test </a>which is done on a biopsy specimen. Prolaris uses genomics to risk stratify who is likely to have their cancer come back in an aggressive form and who will have low-risk disease and not necessarily need to have surgery.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/611/0*55D_sn2465XJdmTZ." /></figure><h3>How do we use genomics to predict who will or will not respond to certain drugs? For example, looking at AR-V7 mutations to predict resistance to drugs like Xtandi (enzalutamide) and Zytiga (abiraterone)?</h3><p>Dr. Morgans: AR-V7 testing, which would potentially help us predict who would respond to drugs like Xtandi (enzalutamide) or Zytiga (abiraterone), is not in clinical practice yet. We do not yet have a Clinical Laboratory Improvement Amendments (CLIA)-certified test that can identify AR-V7 mutations in circulating tumor cells or in prostate tissue that will tell us whether or not a patient will respond to Zytiga (abiraterone) or Xtandi (enzalutamide). At some point, a test like that will likely be commercially available.</p><p>There are clinical trials that are attempting to use the presence or absence of AR-V7 to either enroll people, risk stratify them, or statistically stratify them in the analysis, but it is not a commercially-available and clinically-used test at this point.</p><h3>Do you think that is the path genomics will take in the future?</h3><p>Dr. Morgans: We would love to have a test that could tell us which drugs will work for a particular patient’s cancer and which drugs won’t. We don’t have those tests now, but if and when that information becomes available to clinicians, it will dramatically impact how we treat prostate cancer.</p><h3>Do you think genomics will change how we design clinical trials?</h3><p>Dr. Morgans: It already has to some extent. There are clinical trials that focus around certain mutations or alterations. There are studies that include only patients with AR-V7. There are PARP inhibitor studies that use the presence or absence of DNA repair defects to include or exclude patients. These advances in our understanding of genomics are definitely being integrated into clinical trial design.</p><p>If those clinical trials demonstrate a benefit, it will be another step forward for genomics. Genomics will then have to be incorporated into our practice over time.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/611/0*gmz7k_QvJOOse6t6." /></figure><h3>So it’s just a matter of time before we demonstrate genomics’ usefulness and then it will quickly become integrated into patient care?</h3><p>Dr. Morgans: I don’t know how quickly, but we’re trying. Changing practices in medicine doesn’t always move quickly enough for many of us for important safety reasons in place to protect patients. I would say that genomics has already demonstrated utility. Now we need to finish the clinical trials to really prove that it has a role in clinical practice to help men live longer and better lives. If the studies don’t show this, it won’t be integrated into patient care. I think we are all hopeful that genomics will provide meaningful direction for clinicians as we choose among treatments for men with prostate cancer.</p><p>To this point, there is a great New England Journal of Medicine paper by Dr. Joaquin Mateo and colleagues that performed biopsies on men with advanced disease who had had one or two lines of chemotherapy. <a href="https://www.prostatepedia.net/pages/prostatepedia-back-issues">(See Prostatepedia June 2016 for a conversation with Dr. Mateo about that study.)</a></p><p>The men in the study underwent biopsies and were then treated with Lynparza (olaparib), which is a PARP inhibitor. Those men who had DNA repair defect mutations appeared to have a very high response rate to Lynparza (olaparib) by the criteria included in that study.</p><p>I would say that genomics is already demonstrating the possibility of effectiveness. It just needs to be demonstrated on a larger scale. Mateo’s study only included 50 or so people, not hundreds, as we would have in a definitive, practice changing study. But early signs of clinical utility are definitely there.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/611/0*KfH7iRjpFSHQFbpx." /></figure><h3>Couldn’t a medical oncologist take that study by Dr. Mateo and his colleagues and apply the same principles to his or her own patient?</h3><p>Dr. Morgans: Medical oncologists are doing that, but sometimes we’re limited by insurance. I have patients on Lynparza (olaparib) right now, and we are hopeful that all will go well. We commonly use genomic testing to look at mutations in patients’ prostate cancers, but whether or not an insurance company will pay for us to use an off-label treatment is another question.</p><p>It’s easier in a clinical trial setting, because pharmaceutical companies pay for the cost of the drug. It can be more challenging if you’re not in a clinical trial setting.</p><h3>Are those drugs very expensive?</h3><p>Dr. Morgans: One of my patients paid out-of-pocket for a week for Lynparza (olaparib), and I believe it was in the thousands.</p><h3>What about genomic tests? Are they expensive?</h3><p>Dr. Morgans: That varies by state, by medical institution, and by patient insurance. I have not had trouble getting genomic testing for my patients.</p><h3>What if a patient has already been treated years ago. Is the biopsy tissue usually preserved or does a patient have to request it?</h3><p>Dr. Morgans: The patient doesn’t have to request it if a biopsy or surgery was already done. The patient can talk to his doctor or his family could talk to his doctor and say, “We want to have genomic testing.” The doctor just has to request the test and identify the tissue sample that should be used. Sometimes the patient has preserved samples. If that patient has had a prostatectomy, for example, there may be a recently preserved sample that could be sent.</p><p>However, I would say the most useful genomic testing is done on a metastatic site at the time that a patient is progressing after first line treatment. The reason is that over time, after being treated with multiple medications, prostate cancers acquire new mutations that allow them to become resistant to different treatments.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/611/0*onoowO6d8wC35rKC." /></figure><p>If you sample the initial prostate tumor, you may find a set of mutations that don’t include the ones currently driving that cancer and allowing it to get around the treatments used at that particular time. If there is a way for patients to undergo a biopsy of a metastatic site, that tissue would give them a clearer picture of the mutational or genomic profile of his cancer at that time. There can also be some difference, or heterogeneity, between the genomic profile of different metastatic sites. The genomic profile of one metastatic site may not be exactly the same as another metastatic site. There are stronger driver mutations that we think really help that cancer grow and spread and are driving the growth of that cancer. We hope those mutations would be the same across different metastatic sites, but different sites do acquire different mutations. That has been demonstrated in multiple studies at this point.</p><h3>If you get multiple biopsies over a number of years, should you have all of those tissue samples tested?</h3><p>Dr. Morgans: You could. But I don’t know how many times an individual insurance company will pay for genomic testing. I have had some patients tested multiple times, usually separated by at least a year to two years because they were on one therapy and then another. These are not inexpensive tests. Sometimes an insurance company may say, “We just won’t pay for that.” But I have not had a problem getting a genomic test at least once for patients.</p><h3>Is there anything else patients should know about genomics?</h3><p>Dr. Morgans: Genomics is where we’re going. Being able to predict who will respond to which treatment is our goal. We want to prevent people from being exposed to treatments that aren’t going to help them and stop them from wasting time on therapies that are not going to help them to live longer and better lives.</p><p>I would say that, right now, while genomic testing is happening in the clinic, sometimes it takes a patient asking, “Can I have genomic testing on my tissue?” If you are really interested in getting cutting edge prostate cancer treatments, at least understanding which mutations are present in your personal cancer is the place to start.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2fcb609fa8a0" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Pharmacogenomics + Prostate Cancer]]></title>
            <link>https://medium.com/@jessica_86347/pharmacogenomics-prostate-cancer-ac32dbcd1fa0?source=rss-476d0b9e1b4b------2</link>
            <guid isPermaLink="false">https://medium.com/p/ac32dbcd1fa0</guid>
            <category><![CDATA[prostate]]></category>
            <category><![CDATA[cancer]]></category>
            <category><![CDATA[genomics]]></category>
            <category><![CDATA[pharmacogenomics]]></category>
            <category><![CDATA[mens-health]]></category>
            <dc:creator><![CDATA[Jessica Myers Schecter]]></dc:creator>
            <pubDate>Tue, 07 Mar 2017 16:06:12 GMT</pubDate>
            <atom:updated>2017-03-07T16:06:12.089Z</atom:updated>
            <content:encoded><![CDATA[<p>Dr. William Douglas Figg is the Deputy Chief of the Genitourinary Malignancies Branch and Head of the Molecular Pharmacology Section and Head of the Clinical Pharmacology Program at the National Cancer Institute (NCI).</p><p>Dr. Figg applies pharmacological principles to anti-cancer drug and biomarker development. A large part of his research focuses on the development of novel therapies for prostate cancer.</p><p><a href="http://www.prostatepedia.net/">Prostatepedia</a> spoke with him recently about pharmacogenomics for <a href="http://www.prostatepedia.net/products/prostatepedia-vol-2-issue-number-7-march-2017">our March issue on using genomics to guide treatment.</a></p><h4>How did you come to focus on prostate cancer?</h4><p>Dr. Figg: I finished my Fellowship in drug development at the University of North Carolina at Chapel Hill in 1992 and went to work for Dr. Charles “Snuffy” Myers in the Clinical Pharmacology Branch of the NCI. Dr. Myers was one of the leaders in prostate cancer at the time. I quickly developed a research interest in metastatic prostate cancer and in developing new agents to treat the disease. As a trained pharmacologist, I approached the discovery and development of new anti-cancer agents via a logical flowchart of Go/No-Go decisions.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*iNcirfkHI5mjNcBT." /></figure><h4>What is pharmacogenomics?</h4><p>Dr. Figg: Many physicians don’t fully understand pharmacogenomics.</p><p>If you’re talking to a clinical pharmacologist, pharmacogenomics are variances in genes that handle drugs. Metabolism enzymes and transporters have genetic variances. These variances may mean you need to change the drug dosages, because your body can’t get rid of the drug quickly enough or the drug doesn’t transport well into the cell.</p><p>On the other side, there are somatic mutations associated with a tumor. Somatic mutations are genetic variances inside of a patient’s tumor cell that are different from the patient’s normal DNA. We are now able to target those somatic mutations with drugs that may work in that particular tumor.</p><h4>Is pharmacogenomics used to guide treatment?</h4><p>Dr. Figg: On the clinical pharmacology side, there are 150 drugs that include pharmacogenetics-related information in the approved label. However, about 30% state a requirement or recommendation for genetic biomarker testing. That is not a lot. Many patients haven’t had these tests. <a href="http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm">(See a list of these drugs.)</a></p><p>Some of these are anti-cancer drugs, but most are drugs for other indications that have pharmacogenomic testing in their package insert. It is becoming more widely recognized that we have to do germline DNA testing in order to specify the right dose that works and is safe for an individual.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/600/0*o95tj2aV-rNWqn7K." /></figure><p>With regards to tumors, we have several drugs for which we look at biomarker or genomic indicators of variances in order to specify if you can or shouldn’t take a drug. This is pretty limited for prostate cancer. We’ve done a lot of testing, but the vast majority of our drugs for prostate cancer don’t have a biomarker indicator yet. For other tumors, the biomarkers HER2, BCR-ABL, BRAF, EGFR, PD1, RET, ER, PR and MGMT have been validated.</p><h4>What are the barriers to patients receiving pharmacogenomics testing before taking these drugs?</h4><p>Dr. Figg: Some of it is cost. Some of it is been lack of appreciation that pharmacogenomics testing is important. Some physicians say, “I’ve given this drug for years without a problem.”</p><p>For example, Coumadin (warfarin) has been around for decades. Doctors tend to adjust Coumadin (warfarin) dosages based on bleeding time. We now have genetic markers that can make that first dose specific, so you don’t have to do trial-and-error dosing — increasing and decreasing dosage until you get it right.</p><blockquote>My vision for pharmacogenomics is that eventually we will genotype a child at birth; that information would then go into an electronic medical record (EMRs). Then, every time a physician needs to prescribe something, he or she will already know if that individual can safely take the drug or not.</blockquote><p>Inova Fairfax Hospital in Virginia offers pharmacogenomics testing to all infants born at their hospital (approximately 10,000/year); about 80% of parents consent to the test. Those children will now always have that information in their electronic medical records.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*ekFqsKuNZiWIQYcT." /></figure><h4>Would that reflect a cost-saving? If you could get the right dose for a patient…</h4><p>Dr. Figg: That’s the selling point. For around $500 you can get a panel of about 200 genes that encompasses all of the drug metabolism and transport genes for an individual. Insurance companies are now realizing that it is probably in their interest to do this: it is much better if you can prevent someone from having a bleed or prevent a hospitalization or get more efficacy from a drug. There was a case report in the</p><p><em>New England Journal of Medicine</em> in 2009 about a toddler who had an adenotonsillectomy. Doctors gave him Tylenol 3 (acetaminophen plus codeine) after surgery. Codeine</p><p>is metabolized to morphine via CYP2D6. It turns out this child was an ultra rapid metabolizer of codeine. He died from morphine toxicity. This case struck home with a lot of healthcare providers: we should be doing pharmacogenomics testing more often.</p><p>Camptosar (irinotecan), a colon cancer drug, offers another example. Diarrhea is one of the main limiting factors associated with the drug. We can now genotype the enzyme UGT to predict who will not tolerate Camptosar (irinotecan) because of diarrhea.</p><p>Another example: Mercaptopurine (6MP) is used to treat childhood leukemia and is metabolized by the enzyme thiopurine S-methyltransferase (TPMT), which is polymorphic. That means a small percentage of individuals cannot metabolize through TPMT (0.01% to 1%) and 2% to 20% are intermediate metabolizers. For those deficient in TPMT, you need to give them 10% to 15% of the original dose and give approximately 65% of the normal dose to intermediate metabolizers. Everyone else can tolerate the full dose of that drug quite well. If you happen to give a full dose to a child with a variant for the enzyme TPMT, you could cause serious harm and possible death.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*LD6czsnsMNr7jc8o." /></figure><h4>Are there any implications for prostate cancer patients? Many men with prostate cancer are on a variety of medications for conditions not related to prostate cancer.</h4><p>Dr. Figg: Yes. One, your doctor has to look at drug interactions. There are drugs that inhibit or increase metabolism of anti-prostate cancer drugs.</p><p>My lab at the NCI is at the forefront of trying to understand the variances that predict who responds to chemotherapies such as Taxotere (docetaxel). We are very interested in transporters that may move androgens into the cell. We know that these transporters become up-regulated in advanced prostate cancer.</p><p>We have identified one variant in that genome that could predict your response to androgen deprivation therapy. We’re not at the point of having any kind of guideline for saying you should be doing this type of testing, though. This is still in the research phase. But we’re working towards the end-goal of being able to say, “Let’s genotype you as soon as you’re diagnosed with prostate cancer. We’ll then adjust your therapy based upon that information.”</p><h4>What would you say to a reader who’d like to get tested now?</h4><p>Dr. Figg: I recommend readers talk to their doctors. Depending upon the drug therapy they’re currently on, it may not be necessary right now. If your doctor prescribes something in the future, then it may be worth it. But talk to your doctors. They can order the test.</p><p>Again, it’s a small list and the drugs aren’t common, but a lot of prostate cancer patients are on Coumadin (warfarin). If you’re already on a standard dose and you’re regulated, then it’s perfectly fine. You don’t need to know your genotyping.</p><h4>But if you’re just starting on Coumadin (warfarin), it can really help find the right dose for you.</h4><p>What are some of the barriers to global adoption of genomics to guide treatment? (That is a pretty ambitious goal: to have everybody genotyped at birth.)</p><p>Dr. Figg: We need a full appreciation of the potential side effects of drugs and how we can limit those side effects with genotyping. That appreciation has to come from the medical community. Once they fully understand that they can guide therapy more specifically, or pick the right dose or right drug for an individual, they will be more inclined to do this for their patients.</p><h4>What implications do genomics and pharmacogenomics have for rising health care costs?</h4><p>Dr. Figg: For pharmacogenomics to impact health care costs, we need studies that show we’ve prevented hospitalization by genotyping. We need studies that show we’ve prevented serious complications associated with drugs. And studies that show we had to put fewer patients on a clinical trial in order to get the activity level we’re seeking.</p><p>On the other hand, we can select patients who will have the best response to therapy by genotyping. Instead of doing a 1,000-patient study, we may only have to do a 300-patient study to show that a specific drug is more effective than standard of care. We’re trying to select the population that will have the best response to treatment. This can reduce clinical trial costs and make it faster for drugs to gain FDA-approval.</p><p><a href="http://www.prostatepedia.net/products/prostatepedia-vol-2-issue-number-7-march-2017">Download the March issue.</a></p><p><a href="http://www.prostatepedia.net/pages/subscribe">Or subscribe for 3, 6, or 12 months.</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ac32dbcd1fa0" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What Trump Means For Prostate Cancer]]></title>
            <link>https://medium.com/prostatepedia/what-trump-means-for-prostate-cancer-ea5a6118de10?source=rss-476d0b9e1b4b------2</link>
            <guid isPermaLink="false">https://medium.com/p/ea5a6118de10</guid>
            <category><![CDATA[cancer-research]]></category>
            <category><![CDATA[prostate-cancer]]></category>
            <category><![CDATA[mens-health]]></category>
            <category><![CDATA[donald-trump]]></category>
            <category><![CDATA[affordable-care-act]]></category>
            <dc:creator><![CDATA[Jessica Myers Schecter]]></dc:creator>
            <pubDate>Tue, 29 Nov 2016 20:41:52 GMT</pubDate>
            <atom:updated>2016-11-29T20:41:52.061Z</atom:updated>
            <content:encoded><![CDATA[<p>Jamie Bearse is the CEO of <a href="https://zerocancer.org/">ZERO — The End of Prostate Cancer</a>, a prostate cancer nonprofit organization that advances research, encourages action, and provides education and support to men and their families through patient-centric programs.</p><p><a href="http://www.prostatepedia.net/"><em>Prostatepedia</em></a> spoke with him about the changes President-elect Donald Trump’s administration may bring to prostate cancer.</p><h4><strong>What does a Trump Presidency mean for prostate cancer research?</strong></h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/768/1*JyoadjdeO3ZOTkH4wbZp6A.jpeg" /></figure><p>Mr. Bearse: There are two different sources of government funding for prostate cancer research: the National Institute of Health (NIH) and the Prostate Cancer Research Program (PCRP) within the Department of Defense (DoD).</p><p>Until we have more information about who the Directors of the National Institutes of Health (NIH) and National Cancer Institute (NCI) will be, how the Trump administration will address cancer research, and how they prioritize cancer research against the country’s other needs, the future of research funding at NCI is uncertain.</p><p>The DoD also plays a very significant role in the war on cancer. Within the DoD is a program called the Congressionally Directed Medical Research Programs (CDMRP) that has about two dozen cancer research programs. One of those programs is a prostate cancer program, to which Congress appropriates $80 million.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*RW0n5SJxJogbKcRDVYIb6A.jpeg" /></figure><blockquote>It focuses on taking new, bright ideas from the scientific bench to the patient’s bedside as rapidly as possible.</blockquote><p>It has been a very successful research model that incorporates patient feedback. Peer-reviews by gold-star institutions around the country decide who gets grant funding.</p><p>There have been three new treatments for advanced prostate cancer in the last five years as a result of DoD prostate cancer funding: Xgeva®, Xtandi®, and Zytiga®. The PCRP at the DoD has funded clinical trial research finalizing all three of these agents.</p><p>The Presidential administration has historically not given much philosophical input into medical research funded by DoD because Congress appropriates the program’s funding.</p><blockquote>Control of neither the Senate nor the House of Representatives has changed after the election. In fact, all of the big champions for prostate cancer research funding at the DoD remain in Congress in positions of influence. I’m very hopeful that we are in good shape for prostate cancer research funding at the DoD.</blockquote><p>But there is always a risk, predominantly because Senator John McCain, who was reelected, is an opponent of the CDMRP. McCain is not necessarily against cancer research, but he does not believe that medical research funding belongs in the DoD and has continually tried to eliminate the program through legislation. He also continues to fall short on offering a solution; he just wants to eliminate the program without proposing a vehicle to continue this high-risk, high-reward research in another Federal agency. How many people will support the bills he introduces is a bit of an unknown, but I’m fairly confident that the bills will not pass.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*r9LJKOfmd81XxnpXdepgkQ.jpeg" /></figure><h4><strong>What should patients do if they’re concerned?</strong></h4><p>Mr. Bearse: Every year, we host our ZERO Prostate Cancer Summit in Washington, DC, during which we teach advocates from around the country to be the best advocate they can. We bring patient advocates to Capitol Hill to meet with their elected officials in an attempt to recruit these officials as champions for prostate cancer research. Joining us for that summit is one way to get involved.</p><p>Anybody can apply to the Summit. We have very limited scholarship funding to encourage advocates from particular districts to attend, but the Summit itself is open to everyone.</p><p>Another way to get involved is to sign up for our advocacy alerts, so that you will get an email when issues related to prostate cancer emerge.</p><p>We also do a Call To Action for constituents to call and write to their elected officials about issues that come up.</p><h4><strong>How will the proposed modifications to the Affordable Care Act affect prostate cancer patients?</strong></h4><p>Mr. Bearse: That is uncertain.</p><p>During the campaign, we heard a lot about how Trump’s administration would repeal and replace the Affordable Care Act. But in the last few days, there has been some signaling that there is interest in keeping at least a couple parts of the Affordable Care Act that seem to be popular around the country — covering preexisting conditions and allowing children up to the age of 26 to remain under their parents’ health insurance.</p><p>Those two provisions of the Affordable Care Act are tied into the overall funding mechanism. How will we keep those two provisions while changing the rest of the Affordable Care Act?</p><blockquote>Today, what changes to the Affordable Care Act mean for prostate cancer is uncertain. That is subject to change moving forward.</blockquote><h4><strong>What can patients do if they’re nervous about their own care?</strong></h4><p>Mr. Bearse: If you’re unsure about what all this means for your own battle with prostate cancer, you may want to use ZERO’s patient navigation program, ZERO360. ZERO360 pairs you with a navigator who will stay with you throughout your fight with cancer. This is not a one-and-done phone call. You will be assigned to a navigator who will help answer all of your questions on a rolling basis.</p><p>As the Affordable Care Act potentially changes or does not, as your health insurance potentially changes or does not, we will help direct you in the best possible way.</p><p>Is this a fee-based service?</p><p>Mr. Bearse: It is absolutely free and confidential.</p><h4><strong>Are there any other implications for prostate cancer during the transition?</strong></h4><p>Mr. Bearse: Many prostate cancer patients and advocates are very interested in early detection for prostate cancer. There is a volunteer task force called the United States Preventative Services Task Force (USPSTF) that states that the prostate cancer PSA test doesn’t have any value in saving lives. We disagree.</p><p>We believe that PSA testing is the first step in identifying who has prostate cancer and who does not. There are other steps that help us determine how widespread and aggressive a man’s prostate cancer may be before a he jumps into treatment.</p><p>The USPSTF argues screening men automatically leads to over-treating men. We disagree.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ItDzqY0QROy1FAn8R_YMDA.jpeg" /></figure><p>The USPSTF greatly influences general practitioners. A man will go in to see his doctor for an annual physical expecting the doctor to give him all the tests he needs to make sure that he is healthy. But more times than not, the general practitioner will cite the USPSTF’s stance that prostate cancer screening has no value unless you are in a high-risk group like being African American or have a family history of the disease. We believe that is a problem.</p><blockquote>But the election may have a positive impact on current screening recommendations.</blockquote><p>The Affordable Care Act (Obamacare) ties the USPSTF’s recommendations to mandatory commercial insurance coverage. If Congress reforms or repeals and replaces Obamacare, there could be an impact on the force of the USPSTF’s recommendations and in turn how the USPSTF influences general practitioners’ behaviors or recommendation in for prostate cancer testing.</p><p>This could be positive development for the prostate cancer cause. If the USPSTF’s recommendations are no longer tied to insurance coverage general practitioners may start to look to the National Comprehensive Cancer Network (NCCN) guidelines for prostate cancer screening, which we believe are more favorable.</p><p>We have two indications that this may happen.</p><p>First, there is a bill on Capitol Hill called the USPSTF Transparency and Accountability Act that, if enacted, would require the USPSTF to incorporate a broader spectrum of expertise into its cancer screening recommendations. Congresswoman Marsha Blackburn, a sponsor of the bill, is part of the current Trump transition team, so her thoughts and feelings about the USPSTF may be translated into the Trump administration.</p><p>Another champion for stating that the USPSTF prostate cancer screening recommendations are overblown is Alabama Senator Jeff Sessions, who currently continues to be vetted for a potential cabinet post. He may likewise influence thought on how the USPSTF behaves or influence the Trump administration’s reactions to cancer screening.</p><h4><a href="http://www.prostatepedia.net/">Prostatepedia features conversations about prostate cancer. Download a free issue.</a></h4><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ea5a6118de10" width="1" height="1" alt=""><hr><p><a href="https://medium.com/prostatepedia/what-trump-means-for-prostate-cancer-ea5a6118de10">What Trump Means For Prostate Cancer</a> was originally published in <a href="https://medium.com/prostatepedia">Prostatepedia</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Anger, Shame + Prostate Cancer]]></title>
            <link>https://medium.com/@jessica_86347/anger-shame-prostate-cancer-38b26dda513d?source=rss-476d0b9e1b4b------2</link>
            <guid isPermaLink="false">https://medium.com/p/38b26dda513d</guid>
            <category><![CDATA[prostate-cancer]]></category>
            <category><![CDATA[mens-health]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[cancer]]></category>
            <dc:creator><![CDATA[Jessica Myers Schecter]]></dc:creator>
            <pubDate>Fri, 11 Nov 2016 19:27:08 GMT</pubDate>
            <atom:updated>2016-11-11T19:27:08.402Z</atom:updated>
            <content:encoded><![CDATA[<h3>Shame, Anger + Prostate Cancer</h3><p><a href="http://www.prostatepedia.net/">Prostatepedia</a> spoke with <a href="https://www.youtube.com/watch?v=jk7nEakn5ko">William Goeren</a>, Director of Clinical Programs for <a href="http://www.cancercare.org/">CancerCare</a>, about common issues prostate cancer patients face at diagnosis and after treatment.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*XflVK6PGEIzUnKP5lVbFNA.jpeg" /></figure><p><em>What are some of the common issues prostate cancer patients and their caregivers struggle with?</em></p><p>Mr. Goeren: All people diagnosed with any kind of cancer, or any kind of catastrophic illness, find themselves and their lives altered by the diagnosis. Life is now shifted, as is someone’s identity whether they are the person with cancer or the caregiver. There are now questions about who one is in the world; who one is going to be now; how is one going to cope with the diagnosis; and what is one’s relationship with one’s world, which includes family, friends, profession, short- and long-term goals, and finances.</p><p>Prostate cancer has a profound impact on a man’s sense of self, the identity he has created for himself as a man, and his definition of what it means to be a man. Prostate cancer can have a profound impact on his body image and how he relates to himself and his partner or spouse, as well as to other men.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*acV209QAufK0_36-LaU02g.jpeg" /></figure><blockquote>When a man is diagnosed with prostate cancer, it speaks to the core of a man’s identity because of the prostate cancer’s location and the function of the prostate in terms of sexuality, libido, and bodily function.</blockquote><p>One of the constant and consistent themes when providing psychosocial support and counseling to men with prostate cancer is that many men feel they were not fully informed, not told enough, about the impact and side effects of treatment. This could be because they truly weren’t fully informed in a comprehensive manner, or they didn’t really grasp the depth and complexities of the impact of the treatment’s side effects, or they didn’t or couldn’t hear the information. Men in my support groups say, “The side effects were really downplayed or minimized, or they were sort of secondary to the conversation that my doctor was having with me. I asked about the side effects, but I was led to believe that they would be minimal and temporary.”</p><p>Once they’re in treatment, or have finished treatment, they experience some startling realizations that the changes in their lives might be permanent which then affects quality of life. They’re really quite shocked, stunned, and dismayed at the severity and chronicity of these side effects.</p><p><em>Are they saying that their doctors didn’t tell them about the side effects, or they just didn’t fully understand what their doctors were saying?</em></p><p>Mr. Goeren: Depending on the man, it could be a little bit of both or it could be one or the other. Sometimes they didn’t really grasp it, they didn’t know enough to ask questions in an informed way, or the doctor minimized the severity of the side effects. This is another general theme in oncology.</p><blockquote>Make sure you have prepared your questions for the physician before the appointment. Most people, diagnosed with cancer, are overwhelmed and in cognitive overload when sitting with the oncologist and executive functioning can be short-circuited.</blockquote><p>Another theme I see in both individual men and in support groups is that men are oftentimes left with a sense of shame, of embarrassment, and are often angry.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*09j5oKyJe6h2gCNQqxRM8Q.jpeg" /></figure><p>There is a sense of stigma about the side effects of treatment that they have to confront and begin to understand and cope with, which often presents as anger toward themselves, their loved ones, or life in general. Oftentimes, men struggle with, or are not really in touch with, how deeply emotionally and psychologically they’re responding to these side effects.</p><p><em>Do you think that sense of shame and embarrassment influences whether or not, or when, men seek treatment for those side effects?</em></p><p>Mr. Goeren: I don’t think it really affects when they seek treatment, but I think it does impact their attitudes toward treatment for side effects. And it certainly impacts their attitude toward their doctors.</p><p>In post-treatment, there is a lot of second-guessing and questioning about treatment choices: Did they get the right treatment for them or should they have possibly chosen another treatment? There is a lot of second-guessing and questioning of whether or not they went down the right avenue in terms of treatment.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*wy7qMRcmclXqBXR0JRrkng.jpeg" /></figure><p><em>You’re saying there is a level of distrust of their doctors?</em></p><p>Mr. Goeren: Yes. While they may not question directly their doctor’s advice or suggestions or directions, I think they are very concerned about next steps.</p><p><a href="http://www.prostatepedia.net/products/prostatepedia-vol-2-issue-number-3-november-2016">Download the issue to read the interview in its entirety.</a> <a href="http://www.prostatepedia.net/pages/subscribe">Or, subscribe!</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=38b26dda513d" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Joining A Prostate Cancer Clinical Trial]]></title>
            <link>https://medium.com/prostatepedia/joining-a-prostate-cancer-clinical-trial-177d812a1f65?source=rss-476d0b9e1b4b------2</link>
            <guid isPermaLink="false">https://medium.com/p/177d812a1f65</guid>
            <category><![CDATA[tomasz-beer]]></category>
            <category><![CDATA[mens-health]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <category><![CDATA[cancer-clinical-trials]]></category>
            <category><![CDATA[prostate-cancer]]></category>
            <dc:creator><![CDATA[Jessica Myers Schecter]]></dc:creator>
            <pubDate>Thu, 03 Nov 2016 20:15:17 GMT</pubDate>
            <atom:updated>2016-11-03T20:15:17.666Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*wFmI_KVHaJ2JY-BYKvYR7Q.jpeg" /></figure><p><a href="https://www.ohsu.edu/xd/health/services/providers/?personid=51"><em>Dr. Tomasz Beer</em></a><em>, one of six scientists selected to take part in a global multi-institution research dream team to study treatments for advanced prostate cancer, talks to </em><a href="http://www.prostatepedia.net/"><em>Prostatepedia </em></a><em>about joining clinical trials.</em></p><h3><em>Why should prostate cancer patients consider enrolling in a clinical trial?</em></h3><p>The first reason is linked to one’s own personal care plan. All clinical trials should be well thought out, well designed, and built in a way that would make sense for a patient to consider. We’re not in the business of denying a patient effective therapy, for example.</p><p>Clinical trials are designed to fill the gaps in the standard care offered today. A clinical trial might offer an additional option that doesn’t preclude standard options, but adds to the number of things that we can deploy to try to treat a cancer. It might mean deploying a standard treatment plus a novel agent. In general, for a patient, it can mean an extra treatment option beyond the usual standards that give a patient more strategies than they could get in the context of routine care.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*wydM6giMBkhxymdPKFJi-Q.jpeg" /></figure><p>Another reason is that care on clinical trials tends to be really good. We design the clinical trial protocol very carefully. Monitoring, visit frequency, and attention is inherently really good in clinical trials and the same for every patient.</p><p>In a clinical trial, we have additional personnel paying attention. The visit and monitoring schedule is fully vetted, well thought out, and reviewed by a number of folks along the way — including independent committees that aren’t part of the care team — and then carried out uniformly and universally for each patient. In a clinical trial, you get good attentive care that I think a lot of folks appreciate.</p><blockquote>Beyond that, there are altruistic reasons for being in a clinical trial where one’s personal experience with cancer care is recorded in a broader context and contributes knowledge beyond one’s personal life.</blockquote><p>That doesn’t hold much meaning for some folks, but in my experience for a lot of folks it does. They’ve faced a cancer diagnosis, which is something they never wanted to face. The chance to make a contribution and have what happened to them be known not just for their family’s scrapbook, but for a national effort to improve cancer care, is meaningful for a lot of people. It’s a meaningful reason to consider a clinical trial.</p><h3>Are clinical trials only for men whose cancer has progressed? There is a public perception that clinical trials are for when you’ve exhausted all traditional avenues and now you’re in a last-resort scenario.</h3><p>That public perception is obviously not the whole story nor fully accurate. Every step in the care of a patient can only be improved through a clinical trial. There are clinical trials of screening tests for early detection of prostate cancer. There are clinical trials that attempt to evaluate prostate cancer prevention strategies. That doesn’t mean these trials are always available everywhere, but they do exist.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1000/1*65av_pl6VnCUa566t1PWDA.jpeg" /></figure><p>When it comes to newly diagnosed patients, the issue they face is whether or not they need treatment or can they be observed safely. There are clinical trials of observation looking at things like new imaging modalities and new diagnostic tests that help men decide whether or not their cancer is low risk enough to just be watched and not treated. Local therapies like surgery and radiation are, for the most part, well established, but they can be improved. Sometimes, whether by adding a medication or changing the technique, there is potential for improvement. Often, that is evaluated in a clinical trial.</p><p>All along the way there are clinical trials. It’s not so simple that you have exhausted all treatment options. There are many situations in prostate cancer in which we might have an opportunity to make the treatment that is available better — either more effective, or less toxic, or ideally both.</p><p>There are opportunities to improve things; clinical trials are designed to do just that. When we see patients in our practice here at <a href="https://www.ohsu.edu/xd/">Oregon Health &amp; Science University</a>, our goal is to be able to offer men (not require nor expect, but offer) both standard approaches and investigational approaches at every stage of the disease. We don’t achieve that goal fully, because at any given time there may not be an important research question that is being asked in every single situation that a man might encounter. Even if there were, which there isn’t, one center like ours can’t always do it all.</p><p>It is an aspirational goal, one that we don’t fully deliver on, but we do try to get as close as we can. Often, we’ll have a portfolio of perhaps 10 to 15 clinical trials in prostate cancer. Of those, perhaps a third are focused on very advanced disease where there are few limited options. Perhaps two-thirds are focused on various earlier time points in the disease where treatments are available but have shortcomings.</p><p><a href="https://www.prostatepedia.net/pages/thoughtonjoiningclinicaltrials">Fill out this form to download the entire interview for free.</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=177d812a1f65" width="1" height="1" alt=""><hr><p><a href="https://medium.com/prostatepedia/joining-a-prostate-cancer-clinical-trial-177d812a1f65">Joining A Prostate Cancer Clinical Trial</a> was originally published in <a href="https://medium.com/prostatepedia">Prostatepedia</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>